Design Stock Today

DSGN -  USA Stock  

USD 18.29  2.93  19.08%

Design Therapeutics is selling for 18.29 as of the 28th of July 2021. This is a 19.08 percent increase since the beginning of the trading day. The stock's open price was 15.36. Design Therapeutics has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Design Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2020 and ending today, the 28th of July 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Over 62

Design Therapeutics Stock Profile

The upcoming quarterly report is expected on the 9th of August 2021. The stock is still going through an active downward rally. Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company was incorporated in 2017 and is based in Carlsbad, California. Design Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. more on Design Therapeutics
Design Therapeutics generates negative expected return over the last 90 days
Design Therapeutics has high historical volatility and very poor performance
Design Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 226 K. Net Loss for the year was (8.28 M) with loss before overhead, payroll, taxes, and interest of (5.83 M).
Design Therapeutics has a frail financial position based on the latest SEC disclosures
About 30.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem - Yahoo Finance
Design Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Design Therapeutics SEC Filings
Design Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDesign Therapeutics
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Design Therapeutics report their recommendations after researching Design Therapeutics' financial statements, talking to executives and customers, or listening in on Design Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Design Therapeutics. The Design consensus assessment is calculated by taking the average forecast from all of the analysts covering Design Therapeutics.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Design Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Design Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares17.4 M15.8 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted17.4 M15.8 M
Significantly Up
Increasing
Slightly volatile
Total Assets29.8 M36.5 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities2.6 M2.5 M
Notably Up
Decreasing
Slightly volatile
Current Assets29.6 M36.2 M
Significantly Down
Increasing
Slightly volatile
Current Liabilities2.5 M2.3 M
Notably Up
Decreasing
Slightly volatile
Total Debt621.8 K625.5 K
Slightly Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.01070.0108
Slightly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Design Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Design Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Design Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Design Therapeutics' financial leverage. It provides some insight into what part of Design Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Design Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Design Therapeutics deploys its capital and how much of that capital is borrowed.
Design Therapeutics (DSGN) is traded on NASDAQ Exchange in USA. It is located in 6005 Hidden Valley Road and employs 15 people. Design Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Design Therapeutics's market, we take the total number of its shares issued and multiply it by Design Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Design Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 53.82 M outstanding shares.
Check Design Therapeutics Probability Of Bankruptcy
Ownership
Design Therapeutics retains a total of 53.82 Million outstanding shares. Design Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Design Ownership Details

Design Stock Price Odds Analysis

What are Design Therapeutics' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Design Therapeutics jumping above the current price in 90 days from now is about 87.46%. The Design Therapeutics probability density function shows the probability of Design Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Design Therapeutics has a beta of -0.2718 suggesting as returns on benchmark increase, returns on holding Design Therapeutics are expected to decrease at a much lower rate. During the bear market, however, Design Therapeutics is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Design Therapeutics is significantly underperforming DOW.
 Odds Down 18.29HorizonTargetOdds Up 18.29 
12.49%90 days
 18.29 
87.46%
Based on a normal probability distribution, the odds of Design Therapeutics to move above the current price in 90 days from now is about 87.46 (This Design Therapeutics probability density function shows the probability of Design Stock to fall within a particular range of prices over 90 days) .

Design Therapeutics Historical Income Statement

Design Therapeutics Income Statement is one of the three primary financial statements used for reporting Design's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Design Therapeutics revenue and expense. Design Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Design Stock Against Markets

Picking the right benchmark for Design Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Design Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Design Therapeutics is critical whether you are bullish or bearish towards Design Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Design Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module
Continue to Investing Opportunities. Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Design Stock analysis

When running Design Therapeutics price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Design Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.